A. Jorgensen

FRI0067 Changes in Multi-Biomarker Disease Activity (MBDA) Score Correlate with Changes in Established Disease Activity Measurements in Patients with Early Ra from The Opera Study

C. Brahe, P. Junker, N. Defranoux, 2016 .

Soluble macrophage-derived CD163 is a marker of disease activity and progression in early rheumatoid arthritis.

H. Møller, K. Stengaard-Pedersen, B. Deleuran, 2011, Clinical and experimental rheumatology.

Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA)

M. Østergaard, K. Stengaard-Pedersen, T. Ellingsen, 2015, Annals of the rheumatic diseases.

Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab—a substudy of the optimized treatment algorithm in early RA (OPERA) trial

H. Bliddal, K. Stengaard-Pedersen, H. C. Horn, 2017, Clinical Rheumatology.

Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis

K. Stengaard-Pedersen, H. C. Horn, T. Ellingsen, 2015, The Pharmacogenomics Journal.